HCPLive Network

FDA Approves Alternative Gel Treatment for Bacterial Vaginosis

The US Food and Drug Administration (FDA) has approved a new antibiotic treatment for bacterial vaginosis (BV), announced the drug’s joint manufacturers, Activis and Valeant Pharmaceuticals.

Metronidazole 1.3% is a single-dose treatment for BV, which is the most common vaginal infection for women aged 15-44 years. The pre-filled disposable applicator should be administered once intravaginally at bedtime, according to the drug’s label.

“The approval of Metronidazole 1.3% is a significant milestone for Actavis and provides an important new option with a single-dose treatment for women suffering from BV,” Fred Wilkinson, President of Actavis Global R&D, said in a statement.

The FDA approved Metronidazole 1.3% after reviewing the results of a phase 3 multicenter trial that showed the higher concentration of the vaginal gel was well-tolerated, safe, and efficacious. It is an alternative treatment to the existing BV treatment, MetroGel-Vaginal (metronidazole vaginal gel 0.75%), the manufacturers noted.

“Metronidazole 1.3% gives healthcare providers and women a new safe and effective treatment for BV,” Tage Ramakrishna, MD and Chief Medical Officer of Valeant Pharmaceuticals, added in the statement.

Metronidazole 1.3% is indicated for non-pregnant women. In the drug’s late-stage trial, reported side effects included vulvovaginal candidiasis, headache, vulvovaginal pruritus, nausea, diarrhea, and dysmenorrhea.

Further Reading
The FDA has approved the first human papillomavirus (HPV) DNA test for primary cervical cancer screening.
Inhibiting an enzyme called Src kinase may be a potential new treatment for a rare lung disease known as lymphangioleiomyomatosis.
Janssen will test the combination simeprevir 150 mg and sofosbuvir 400 mg in approximately 400 hepatitis c treatment-naïve and treatment-experienced patients.
More Reading
$related2$
$AD300x250BB$